Protokoly_diagnostiki_i_lechenia_zabolevany

& , & 3 % -( V 10 1 , % 10 ., " 10 )* 0,5-3,0 2-3 & " & ( , ).

! &$ % " &$ ( * 20 , * 20 , 3 20 ) - "& " 2-3 . % & & +2-(*).

' & 3-4 . "$ : & $ & , $ , & $ , $ -.

" – , .

( " 10 ) / "$– ( , , )

H # , , " " & : *, *.

" : & . @& , % " #& - * 0,25-1,0 / 3-4 & 2030 . . / - %# " * ( 1-2). _ & 3- – 6 .

< & " % $ $( - " ) % .

" & :

1.* 20 , 40 .;

2.* 20 .;

3.*? + 15 ;

4.* 4500 >@, ;

5.*@ 10 .; 6.*/ 250 , 500 . .; 125 , 250 /5 ;

7.*@ 40 , 80 .; 40 /2 . V

" & & :

1.10 % ; 1 .; 10 " ;

2.* 250 , 500 .;

3.*/ 125 .;

4.* 0,2% .

,- ! :

, "

/ , & :

1.Chronic pancreatitis. EBM Guidelines. 4.3.2005 Author: Pauli Puolakkainen. Article ID: ebm00209 (009.031)

2.American Gastroenterological Association Medical Position Statement: treatment of pain in chronic pancreatitis. Gastroenterology 1998 Sep;115(3):763-4.

3." , & : . . /. M.J. K " , B.+. @ , '.B. , .6. G . — 2- ., . — 6.: 7 ;?-6>@, 2002. — 1248 .: .

4.@ 3 / .< ?.?., - 6.2002

* – , # (% % )

<

: 04-042

"$ &: " :

& ! :

1. " & ;

2.& " , # ;

3._'1.

J42 G " "

) : < - , $# "3 % 2 , 3 & " " .

$ :

1.;

2.;

3.;

4.-;

5..

* :

1. , , , , " ;

2.%$# ;

3." ;

4.;

5." J-;

6." % &;

7. " ;

8." ;

9.;

10.&-3 " % . " : , 3 .

" :

:

1.& " & % % " ;

2.( & , , );

3.;

4." " .

5 :

1.# (6 );

2.# " ;

3.R– .

:

1." ;

2.3, " # ;

3.# / ;

4., ; 5. .

" &

1.# (6 );

2.# " ;

3.# ;

4.? " & .

" & &

1.;

2..% ;

3.B ;

4.< ;

5.7 ;

6.& .

+ :

1.< " ( ): ( *, b2-( *, & ,) – .*. ".

2.6 " ( *, *, *, *).

3.( ).

4.6 % ( % ).

5.? & .

6.& ( ): , ( ).

7.B ( ).

8..

? "$ " " 3 . " " " 3 " 7-14 ." & in vitro & 3 3 ". + " & . ?

* – 15 10-14 & 3 * – 4010-14 & .

/ * 40 / / , 2 , 10-14 & . H & 1,5 @ " &

& " 5 \ \ &, 5 .

" & :

1.*B 100 , 3 &;

2.*! & 100 / , 3 &; 2 , 4 .; 20 ;

3.*; 100 , 200 , 300 /; 350 .

4. *? 30 ; V 15 /2 , ; 15 /5 , 30 /5 ; 5. *? 500 , 1000 ; 250 ; 500 ; 250 /5 &;

6.*? + 625 .;

7.*/ 250 , 500 .;

8.*? 125 , 500 ; 250 ; 200 /100 .

9.*B & 150 – 10 \ .

" & & :

1.*_ 3 & 200 ;

2.*/ V 2% 2 ; 100 , 200 .;

4.* 250 , 500 , .;

5.* 250 , 500 .;

6.*7 250 , 500 , .

,- ! :& " , , # ,_'1, " ".

/ , & :

1.Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for infant with bronchiolitis. Cincinnati (OH): Cincinnati Children's Hospital Medical Center; 2001 Nov 28. 9 p.

2.Bronchitis. Philadelphia (PA): Intracorp; 2005. Various p.

3.Guideline For The Management Of Acute Exacerbation Of Chronic Bronchitis (AECB), Alberta medical Association, 2001

4.' & % .

. ' ), 6) , 2003

5.@ & . >% " . ' 3. 6 , 6 ! , 2004.

6." $# " , & : ./ . M.J. K " , B.+. @ , '.B. , .6. G .- 2- ., . – 6.: 7 ;?-6>@, 2003. – 1248 .

* – , # (% % ) ** - " & , "$ &

A 8 12 %

: 06-070

"$ &: " :

& ! : 7 +. pylori. ) % , « » ( )" % .

$# ," % .

$ :

I. :

1.D : & ; & .

2.@ : & ; & .

3.! " % . II. 3 :

1.? Helicobacter pylori.

2.+ Helicobacter pylori.

III. " 3 " . IV. : % ; " 3 .

V. ! : % ; . VI. .

VII. % : ; % ; % .

VIII. % : " ; ; ; ; .

* :

1." Helicobacter pylori;

2.& ;

3." % & - & , " & & ;

4.;

5..

" : , 3 ( % ).

" :

1.% , % [ ;

2.& % " : & , , " ;

3.& %[ " , H. pylori, $# 3 ;

4.& % #[ &$ $" ;

5.& # ( $# ).

5 :

1._7 @!;

2.?J;, ?!;, ;

3.& ;

4.3 .

2." ( , , % , % . .);

3.- ;

4.% 12- % & & & , % & " 6-8 &

" " % $" .

" & :

1.# (Er, Hb, L, , ! 7);

2.# " ;

3.! ;

4.;

5.H)B $ ;

6.7 ;

7." ;

8.! " +- D ; ( );

9.@ H.pylori ( & , HpSA , IgG + , ,-);

10.& .

" & & :

1.7

2.;

3.7 3 ;

4.3 ;

5.B % " ;

6." Fe;

7.& ;

8." D ; .

+

+ " :

@ $" $, $# $# "( , , "[ ). , 5-6 .

6 " % /.

'6 (2000 .) " + (B ),

# . B , " % & + & 3 % " 18 " , " " % &100% " . B , % & % " , $ & & , $ % & H.pylori. ,B $ & &$.B , " B ,

7,5 / (max-500 ) + ** 20-30 / (max 1000 ) **

, . '$" . .

:

1.> & " $ 3 , & [ .

2.> & 3 , 3 " , " " & " ( , ).

3.> & , " 3 ,& " & & +. pylori & .

4.& " " " $& , $.

" . ", - ( * * 20 1-2 &, 30 2 &, 3 20 2 &).

@ & , % " #

! &$ % & , & 3 % " ( ) 102-3 &. — (6 , ? &, _ $&),( & , -, , & ), " >1( ), " ( , )(6 , ). % & & " -4 & /7/. 3 " % " % ,, " * 10 000 >@ 3 " 2 &.

7 & " % $ 3 " " 8, & — " 4 .

" & :

1. * 20 , 40 .; 2. ** 20 .;

3. * 250 , 500 .; 4. **? 500 , 1000 ; 250 ; 500 ; 250 /5 ; &; 5. *@ 10 .;

6. **_ 40 ; 20 V ;

7.? 5,0 ;

8.**' 120 .;

9.**6 250 .; 0,5 100 .

" & & :

1.10 % ; 1 .; 10 " ;

2.200 ;

3.4500>@, .

/ , & :

1.Prodigy guidance – Dyspepsia – proven DU, GU, or NSAID-associated ulcer. NICE 2004Management of Helicobacter pylori Infection. MOH Clinical Practice Guidelines 9/2004

2.New Zealand guidelines group/ Management of dyspepsia and heartburn, June 2004.)

3.Management of Helicobacter pylory infection. Ministry of health clinical practice guidelines 9/2004/

4.Guidelines for clinical care. University of Michigan health system. May 2005.

5.Practice guidelines. Guidelines for the Management of Helicobacter pylori Infection/ THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 93, No. 12, 1998.

6." , & : . . /. M.J. K " , B.+. @ , '.B. , .6. G . — 2- ., . — 6.: 7 ;? -6>@, 2002. — 1248 .: .

7.6.M.@ . " 3 .-6, 1999.

8.@ 3 / . ?.?.< – 6.2002, 592 .

9.Kawacami Y., Akahane T., Yamaguchi M. et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thiother derivative alone and in combination with other antimicrobials againts recent clinical isolates of H.pylori. Antimicrob Agents Chemother, 2000. vol.44, N2.-P.458-461.

10.H. Holtmann, P. Bytzer, M. Metz, V. Loeffler. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease/ Aliment Pharmacol Ther 2002; 16: 479-485

* – , # (% % )

**- " & , "

$ &

!

"

( -" )

# 2006 .

. ' % " ( &

$ : (D , 1980):

* :

1.% 3 ;

2." ;

3.! ;

4.' % ;

5.6 ;

6.B ;

7.; % ;

8.6 &;

9.% ( 32 & );

10.) ;

11.G ;

12.;

13." ;

14.@ & ;

15.B ;

16.! & & ;

17.L & & &.

5 :

1.- " ;

2. - ; , H)B,